Prostate cancer discovery opens door to more tailored treatments | ScienceDaily

 

  • The concept of chimeric RNA formation - showing how normal RNA from separate genes (Gene A and Gene B) undergoes splicing mechanisms to create fusion RNA molecules
  • The population-specific patterns discovered in the research - visually representing the different chimeric RNA patterns found in Western men versus Chinese men
  • The clinical implications of this discovery - highlighting the potential for improved diagnostics and targeted therapies

    • Genetic "Chimeras" Could Revolutionize Prostate Cancer Treatment

    New research reveals how personalized therapies targeting unique RNA signatures may improve outcomes across different populations

    A groundbreaking discovery by researchers at the University of Virginia Cancer Center could transform how prostate cancer is treated worldwide. Scientists have identified that prostate cancer has distinct genetic properties in different groups of men that can be targeted to develop more precise and effective treatments.

    Understanding Chimeric RNA

    The international research team, led by Dr. Hui Li from UVA's Department of Pathology, focused on what are known as "chimeric RNA" in Chinese men and found both similarities and differences compared to those seen in Western men. These specialized RNA molecules can contribute to cancer growth and are widely used as both indicators of cancer and targets for cancer treatment.

    Chimeric RNA represents a fascinating area of cancer biology. These molecules combine operating instructions from two or more different genes and can influence tumor formation and growth by producing specific proteins or altering gene activity. As noted in previous research, "chimeric RNAs are expected to increase the proteomic diversity through chimeric proteins or altered regulation" of genes.

    Population-Specific Patterns

    The UVA team made a remarkable discovery when comparing data from the Cancer Genome Atlas and the Chinese Prostate Cancer Genome and Epigenome Atlas. They found that Chinese men had several distinct chimeric RNA patterns, including differences in cancer epithelial cells as well as in macrophages and T cells (immune cells found in and around tumors).

    This research is particularly significant given that Asian populations have a higher ratio of prostate cancer deaths to new cases (40%) compared to Europe (18%), Northern America (10%), or the global average (25%).

    Dr. Li emphasized the importance of this research: "Prostate cancer is a worldwide problem. It is the most common cancer in men, with clear racial disparities." He noted that over 70% of Asian prostate cancer patients are diagnosed at intermediate or advanced stages, contributing to poorer outcomes.

    Implications for Treatment

    The researchers were able to validate over 100 chimeric RNAs, the largest list in the field, with many showing clear diagnostic and prognostic potential. By targeting chimeric RNA specific to different populations, doctors may be able to develop more tailored prostate cancer treatments.

    "This is the first comparison between two prostate cancer populations focusing on chimeric RNAs," Dr. Li explained. "It is also the first study to examine chimeric RNAs in different cell types within cancer."

    The potential applications extend beyond prostate cancer. The researchers note that "chimeric RNAs as such represent a hidden repertoire for biomarkers and/or therapeutic targets" that could be applied to many forms of cancer.

    Connecting to Immunotherapy Advances

    This research comes at a time when immunotherapy is showing increasing promise for prostate cancer patients. Recent developments in T-cell therapies and immune checkpoint inhibitors are beginning to overcome the historical resistance of prostate cancer to immunotherapy approaches.

    A recent clinical trial involving an experimental drug called AMG 509/Xaluritamig saw a reduction in blood levels of prostate-specific antigen (PSA) in nearly half of participating patients, while a quarter showed tumor shrinkage on scans. These advances in immunotherapies, combined with our improved understanding of chimeric RNA, suggest a future where treatments can be truly personalized based on a patient's specific genetic profile.

    Looking ahead to future cancer research in 2025, experts predict "advances in technologies such as spatial transcriptomics, single-cell sequencing, and artificial intelligence" will help further our understanding of the tumor microenvironment, potentially resulting in more effective targeted therapies and immunotherapies.

    What This Means for Patients

    For prostate cancer patients, this research offers hope for more effective treatments tailored to individual genetic profiles. The ability to identify specific chimeric RNA signatures could lead to:

    1. More accurate diagnosis and prognosis
    2. Earlier detection of aggressive forms
    3. Personalized treatment approaches
    4. Better outcomes for patients across different populations

    By better understanding the genetic differences in prostate cancer across populations, researchers are opening the door to precision medicine approaches that could significantly improve survival rates.

    Sources

    1. Wang, Q., Yu, S., Jie, J., et al. (2025). Profiling chimeric RNA in prostate cancer in Chinese cohorts reveals similarities and differences compared to Western populations. iMeta, 4(2). DOI: 10.1002/imt2.70014. https://www.sciencedaily.com/releases/2025/04/250424120803.htm
    2. University of Virginia Health System. (2025, April 24). Prostate cancer discovery opens door to more tailored treatments. ScienceDaily. https://www.sciencedaily.com/releases/2025/04/250424120803.htm
    3. University of Virginia Health System. (2025, April 23). Prostate Cancer Breakthrough Paves Way for Custom Care. Mirage News. https://www.miragenews.com/prostate-cancer-breakthrough-paves-way-for-1449497/
    4. He, M., Zhang, D., Cao, Y., et al. (2023). Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects. Heliyon, 9(8). https://pmc.ncbi.nlm.nih.gov/articles/PMC10469587/
    5. National Cancer Institute. (2025). Advances in Prostate Cancer Research. https://www.cancer.gov/types/prostate/research
    6. American Association for Cancer Research. (2025, January 10). Experts Forecast Cancer Research and Treatment Advances in 2025. https://www.aacr.org/blog/2025/01/10/experts-forecast-cancer-research-and-treatment-advances-in-2025/
    7. MD Anderson Cancer Center. (2024, May 10). What's new in immunotherapy for prostate cancer? https://www.mdanderson.org/cancerwise/what-s-new-in-immunotherapy-for-prostate-cancer-treatment.h00-159697545.html
    8.  Prostate cancer discovery opens door to more tailored treatments | ScienceDaily

    Comments

    Post a Comment

    Popular posts from this blog

    Dr. Christopher Kane of UCSD Health Appointed Chairman of the American Board of Urology

    Image
      Dr. Christopher Kane of UCSD Health Appointed Chairman of the American Board of Urology SAN DIEGO, May 21, 2025 - Dr. Christopher Kane, a distinguished urologist and Professor of Urology at UC San Diego Health, has been appointed Chairman of the American Board of Urology (ABU), the organization announced today. Dr. Kane, who has served as CEO of UC San Diego Health Physician Group and Dean of Clinical Affairs at the UC San Diego School of Medicine, brings decades of experience in urologic oncology and leadership to this prestigious national position. Extensive Academic and Research Background Dr. Kane earned his medical degree from Uniformed Services University in Bethesda, Maryland, followed by a residency in urology at the Naval Medical Center San Diego and a fellowship in urologic oncology at the National Cancer Institute. He joined the UCSD faculty in 2007 after serving as a Navy physician for 12 years. As the C. Lowell and JoEllen Parsons Endowed Chair in Urology, Dr. ...
    Read more

    A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

    Image
    Vanquish® Water Vapor Ablation System, Francis Medical Steams Out Prostate Cancer The Vanquish® Water Vapor Ablation System, developed by Francis Medical, Inc. , represents an innovative approach to treating prostate cancer using water vapor (steam) to ablate cancerous tissue. This minimally invasive technique aims to target and destroy prostate cancer cells while minimizing damage to surrounding healthy tissue, potentially reducing common side effects associated with traditional treatments like surgery and radiation, Mechanism of Action:  The Vanquish system utilizes the thermal energy stored in sterile water vapor to ablate cancerous prostate tissue. During the procedure, a catheter is inserted through the urethra into the prostate, delivering water vapor directly to the targeted tissue. As the vapor condenses back into liquid, it releases stored thermal energy, effectively destroying the cancerous cells. This method is designed to respect the prostate's natural boundaries, ...
    Read more

    Researchers develop low-cost device that detects cancer in an hour | ScienceDaily

    Image
    Summary Sanjay S. Timilsina , currently Lead Scientist, StataDx, a spinoff from Wyss Institute, former Postdoctoral Fellow at Harvard Medical School and the Wyss Institute at Harvard University, PhD from UTEP Department of Chemistry & Biochemistry, and XiuJun Li full Professor in the Department of Chemistry and Biochemistry and of Forensic Science, & Environmental Science and Engineering, at the University of Texas at El Paso (UTEP) have developed a new portable device for cancer detection that offers several advantages over traditional methods: Key Features: - Low cost (a few dollars per device, <8 cents per assay) - Provides results in about 1 hour (vs. 12-16 hours for traditional methods) - Approximately 10 times more sensitive than traditional methods - Portable and doesn't require specialized instruments - Can detect both CEA colorectal and PSA prostate cancer biomarkers - Uses a "paper-in-polymer-pond" structure to analyze blood samples How it works: - U...
    Read more